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Abstract
Rationale Propranolol is found to reduce physiological
hyper-responsiveness in post traumatic stress disorder
(PTSD), possibly by affecting reconsolidation after the
reactivation of traumatic memories. Cortisol is found to
attenuate declarative memory retrieval, but it is unknown
whether it also reduces physiological responses to emotional
memories.
Objectives To examine whether the effects of propranolol
on physiological responding to emotional memories can
also be found in healthy controls and to investigate the
immediate and prolonged effects of cortisol on physiolog-
ical responding to emotional memories, we tested these
effects in 79 healthy young men.
Materials and methods After preparing a script of a negative
disturbing memory, participants were instructed to imagine
this event 1 week later after ingestion of either 35 mg cortisol,
80 mg propranolol, or a placebo. Physiological responding to
the script-driven imagery was recorded. Another week later,
after washout, the imagery was repeated again. During all
three sessions as well as 8 months later, subjective emotional
reactions to the memories were assessed.
Results The emotionality of the memories was reduced
over time, which was not affected by the treatments,
however. The personal emotional script did evoke higher
skin conductance responses than a neutral story, which
decreased 1 week later, but no effects were found of either
propranolol or cortisol on this responsiveness.
Conclusions Whereas healthy males do show psychophys-
iological responding to personal emotional scripts, the effects
of cortisol and propranolol on physiological responses to
emotional memories might be specific to clinical groups
characterized by hyper-responsiveness, like PTSD. Future
studies using longer-acting doses and more elaborate
reactivation procedures in both healthy men and women
could shed more light on the effects of cortisol and
propranolol on psychophysiological responding to emotional
memories.
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Stress hormones like cortisol and (nor)adrenaline have been
found to affect human memory processing (Cahill et al.
1994; Lupien and McEwen 1997; Wolf 2008). These effects
are dependent on several variables, including the stage of
memory processing and the emotionality of the memories
involved. Encoding and consolidation stages seem to be
enhanced by both elevated cortisol and adrenaline levels
(Andreano and Cahill 2006; Buchanan and Lovallo 2001;
Cahill and Alkire 2003; O’Carroll et al. 1999), while they are
impaired after blocking adrenaline by means of selective
beta-blocking agents like propranolol (Cahill et al. 1994; van
Stegeren et al. 1998). On the other hand, retrieval seems to
be impaired by increased cortisol levels (de Quervain et al.
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2000; Het et al. 2005), while not much is known about
the effects of adrenaline manipulation before retrieval
(Chamberlain et al. 2006; de Quervain et al. 2007).
Regardless of the memory stage, the effects of cortisol seem
to be dependent on the emotionality of the memories involved.
That is, effects are stronger when memories are arousing
(Buchanan and Lovallo 2001; Kuhlmann et al. 2005a, b)
or when the testing environment elicits enough arousal
(Abercrombie et al. 2005; Kuhlmann and Wolf 2006;
Tollenaar et al. 2008a). Likewise, blocking adrenergic
activation impairs the encoding mostly of emotional material
(Cahill et al. 1994; van Stegeren et al. 1998).
As it has been shown that encoding and retrieval can be
affected by stress hormones, lately, an increasing interest in
manipulating postretrieval processes has arisen (e.g.,
Diergaarde et al. 2008; McCleery and Harvey 2004). If it
would be possible to affect memory traces after they have
been formed and retrieved, this could improve the treatment
of stress- and memory-related disorders, like post traumatic
stress disorder (PTSD) and phobias (de Quervain and
Margraf 2008; Debiec and Ledoux 2006). Promising in
this view is animal research that has shown that stress
hormones like corticosterone (a glucocorticoid that resem-
bles cortisol, but is naturally more abundantly present in
rodents) and beta-adrenergic blocking agents like propran-
olol can affect long-term memory when administered
during or after reactivation of the existing memory traces
(Abrari et al. 2008; Cai et al. 2006; Debiec and Ledoux
2004; Maroun and Akirav 2007; Przybyslawski et al. 1999;
Tronel and Alberini 2007; Yang et al. 2005). Processes that
are thought to be influenced by these drugs are postretrieval
mechanisms like extinction and reconsolidation (Suzuki et
al. 2004). While extinction may lead to new memories that
are formed during habituation to emotional memories (or
conditioned anxiety responses), reconsolidation is thought
to be a process during which the original memory trace
becomes temporarily labile after reactivation, and thus
prone to change. If extinction could be enhanced or
reconsolidation impaired, it should be possible to attenuate
existing (traumatic and anxious) memories.
Based on the above findings, both cortisol and propran-
olol have been proposed to lead to lasting reductions of
emotional memory traces after exposure to traumatic
memories and phobias. Moreover, both substances have
already been included in clinical trials. Preliminary results
have indeed shown that administration of both cortisol and
propranolol can diminish PTSD and anxiety symptoms.
Namely, perioperative cortisol administration reduced
PTSD symptoms at 6 months after cardiac surgery
(Schelling et al. 2004) and repeated cortisol administration
was found to reduce symptoms of re-experiencing and
intensity of the traumatic memories in PTSD patients
(Aerni et al. 2004) and also to reduce phobic fears (Soravia
et al. 2006). Propranolol administered within hours of a
traumatic experience was found to reduce subsequent
physiologic responding to traumatic memories (Pitman et
al. 2002) and development of PTSD symptoms (Vaiva et al.
2003). Although these studies show clinically relevant
effects of cortisol and propranolol, the mechanisms through
which these substances work are still unclear.
During reactivation, two different memory routes could
be affected that are not mutually exclusive: (1) declarative
memory traces might be weakened and (2) the physiolog-
ically arousing components of emotional memories might
be attenuated. While the first route is thought to be mostly
mediated by the hippocampus and prefrontal cortex, the
amygdala is thought to be engaged in the emotional
reactions to memories, but these systems are highly
interlinked (e.g., Greenberg et al. 2005). Therefore, it is
also of interest to know whether these routes can be
affected separately. In order to test the first possibility, we
previously studied the immediate and prolonged effects of
both cortisol and propranolol administration on declarative
memory retrieval. We found that declarative memory can
be impaired long-term when memories are reactivated
during high levels of stress (Tollenaar et al. 2008b) or after
cortisol administration (Tollenaar et al. 2008c), in line with
animal research (Cai et al. 2006; Maroun and Akirav 2007).
In contrast, we did not find any immediate or long-term
effects of propranolol on declarative memory after reacti-
vation (Tollenaar et al. 2008c), which is consistent with
findings by de Quervain et al. (2007).
In line with the idea that the physiologically arousing
components of emotional memories can be attenuated, a
recent study by Brunet et al. (2008) has shown that
postretrieval propranolol administration diminished physi-
ological responses to script-driven imagery of traumatic
memories in PTSD patients. These results might indicate
that propranolol is more effective in attenuating emotional
components of memories than reducing declarative memo-
ry. Het and Wolf (2007) found that cortisol administration
in healthy young women led to reduced negative mood
after a psychosocial stress task. They suggest that this effect
might be mediated by a slight impairment in retrieving the
just-experienced negative stress episode and/or from a
reduced retrieval of previous negative episodes related to
the stressor. This finding indicates that cortisol administra-
tion might affect the emotional experience of negative
events and thus possibly also of negative memories.
To investigate whether the physiologically reducing
effects of propranolol in PTSD patients can also be found
in a healthy human population and to examine whether
cortisol has similar properties of attenuating the physiolog-
ical components of emotional memories, we have con-
ducted the present study. In the present study, we
investigated the immediate and prolonged effects of both
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cortisol and propranolol administration on physiological
responding to script-driven imagery of negative, disturbing
memories in healthy young men after reactivation of these
memories, as well as on subjectively experienced emotions
to these memories. We expected both propranolol and
cortisol to influence postretrieval processes leading to
diminished physiological responding to the emotional script
in comparison to a neutral story 1 week after treatment.
Materials and methods
Participants
Eighty-five Dutch male students were recruited through
advertisements at colleges and the Leiden University as part
of a larger study on memory for which results will be
presented elsewhere (Tollenaar et al. 2008c). Only men
were selected because of possible confounding effects of
menstrual cycle and contraceptive pills on the relation of
cortisol and propranolol treatment with memory (Cahill and
van Stegeren 2003; Kuhlmann and Wolf 2005). Participants
were screened before inclusion. Inclusion criteria were: no
reported history of disease or psychiatric problems, no
current use of prescribed medication including corticoste-
roid-containing ointments, no chronic disease requiring
medical attention including diabetes, allergies, and asthma,
no use of psychotropic drugs, no alcohol abuse, smoking
less than ten cigarettes per day, age between 18 and
35 years, an estimated body mass index (BMI) between
19 and 26 kg/m2, and blood pressure levels over 100/
70 mmHg. Before participation, written informed consent
was obtained, and after participation, participants were
rewarded with either course credits or a monetary compen-
sation (40 Euros). The study protocol was approved by the
Medical Ethics Committee of the Leiden University
Medical Center.
To minimize influences on baseline cortisol levels, partic-
ipants were instructed to refrain from drinking any sweet or
caffeinated drinks and eating heavy meals on the morning of
the second (treatment) session. Furthermore, they were
instructed not to eat or drink anything but water and not to
smoke an hour before the second session would start.
Of the 85 recruited participants, two men were excluded
after the first session due to low blood pressure. Two
participants were ill during one of the sessions and one
person dropped out after the first session. We excluded one
more participant due to a fire alarm on the second session
during the imagery task. Hence, 79 participants completed
the study. Participants were randomly assigned to one of
three experimental groups in a double-blind between-
subjects design (placebo: N=26, cortisol: N=26, propran-
olol: N=27). Dependent on group, 35 mg hydrocortisone,
80 mg fast-acting propranolol, or a placebo was adminis-
tered orally, in identical capsules.
Table 1 shows the demographic variables of the partic-
ipants per group. No differences between groups were found
for BMI, anxiety (STAI-trait), and general psychopathology
(Symptoms Checklist-90 [SCL-90]). Age was significantly
higher in the cortisol group compared to the placebo group
(t(32)=2.38, p<0.05) due to the fact that the two oldest
participants (aged 30 and 32 years) were randomly assigned
to the cortisol group. Depression scores on the Beck
Depression Inventory (BDI-II) were marginally higher in
the control group compared to both the cortisol (t(44)=1.74,
p=0.09) and propranolol group (t(50)=1.89, p=0.07).
Psychophysiological measures
Saliva samples were obtained using Salivettes (Sarstedt,
Germany) to measure unbound cortisol and alpha-amylase
levels. Alpha-amylase has been shown to be an estimate of
adrenergic activity (Nater et al. 2006; Rohleder et al. 2004)
and is sensitive to beta-blockage by propranolol (van
Stegeren et al. 2005). Saliva samples were stored at −20°C
prior to analyses. The saliva samples were analyzed by the
Kirschbaum Lab, Technical University of Dresden (see
Rohleder et al. 2006). One person (from the propranolol
group) had a missing saliva sample and three people (one
from each group) had a missing alpha-amylase sample.
Table 1 Demographic variables (mean±SD)
Group Placebo Cortisol Propranolol
(N=26) (N=26) (N=27)
Age 19.54 (1.39)* 21.35 (3.61)* 20.74 (2.21)
BMI 22.13 (2.38) 22.40 (1.98) 21.90 (2.31)
Depression (BDI-II) 6.54 (4.46)** 4.69 (3.04)** 4.46 (3.41)**
Anxiety (STAI-trait) 33.81 (9.26) 33.73 (9.08) 31.56 (6.89)
Psychopathology (SCL-90) 28.50 (25.26) 28.73 (23.23) 27.81 (19.88)
BMI body mass index, BDI-II Beck Depression Inventory II, SCL-90 Symptoms Checklist-90
*p<0.05, significant difference in age between the placebo and cortisol groups; **p<0.10, marginally significant difference in depression scores
between the placebo, cortisol, and propranolol groups
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These participants were left out of the repeated-measures
analysis of variance (RM-ANOVA) with cortisol or alpha-
amylase as a factor.
Heart rate and blood pressure were measured with an
automatic upper arm blood pressure monitor (OMRON,
M6) once before (t=0) and three times after pill ingestion
(at t=75, 110, and 135 min) to further asses adrenergic
functioning. In addition to each physiological recording,
participants were given a questionnaire with seven ques-
tions on the intensity of subjective experiences of tension,
anxiety, insecurity, irritation, motivation, mood, and tired-
ness. Answers were given on visual analog scales (VAS) of
100 mm in length, leading to a score from 0 (not at all) to
100 (extremely) on each scale.
During the script-driven imagery procedures, heart rate
and skin conductance level (SCL) were continuously
measured at 50 Hz using a stimulus presentation and
physiological analyses software package developed by the
University of Amsterdam (VSRRP98; http://www.test.uva.
nl/ozi_psychology/index.php?Page=Software). Heart rate
was measured with a finger plethysmograph on the non-
dominant ring finger. SCL was measured with two 1-cm2
electrodes attached to the middle phalanx of the index and
middle finger of the same hand. SCL fluctuations (SCLfluc)
were calculated in Matlab (R2007a) by peak detection on
the first derivative of the SCLs after a second-order
forward/backward 1 Hz low pass filter. Because statistical
analyses on the SCLfluc responses showed similar patterns
to SCL responses, we will not report the SCLflucs in the
“Results” section. For nine participants, heart rate was not
measured on one or more time points due to technical
failure (placebo: N=5, cortisol: N=4). These participants
were left out of the RM-ANOVAs with heart rate respond-
ing as a factor.
Questionnaires
The BDI-II (Beck et al. 1996; van der Does 2002) was
administered to assess depressive feelings in the past 2 weeks,
a Dutch version of the STAI-trait (Spielberger 1983) to
measure the level of generalized anxiety, and the SCL-90
(Arrindell and Ettema 1986) to assess psychological symp-
toms and general psychopathology during the last week.
A questionnaire about the personal script consisted of
questions on emotional arousal, valence, re-experiencing,
fear, anger, sadness, importance, and how often one had
thought about the event. All were measured on seven-point
Likert scales, ranging from 1 (very low) to 7 (very high).
Procedure
Participants came to a laboratory at the Faculty of Social
and Behavioral Sciences in Leiden for three sessions. The
interval between each session was 1 week (see Fig. 1 for an
overview of the test sessions). In the first session, screening
measurements of blood pressure and heart rate were taken
with the OMRON after three rest periods of 4 min, as well
as a baseline measure of heart rate and SCL during a 4-min
continuous measurement period. During this first session, a
personalized script was prepared in 15 min (according to
methodology of Bremner et al. 1999; Pitman et al. 1987).
Participants were asked to write down a negative disturbing
event that still triggered emotional feelings of anxiety,
anger, or fear on a script preparation form in the present
tense. Participants also filled in a short questionnaire on the
intensity of emotions the memory evoked. After that
session, before session 2, the experimenter reviewed the
writing and composed and recorded a script approximately
1 min in length for later audio playback. At the start of the
second session, baseline measurements of heart rate and
blood pressure were assessed and baseline saliva samples
obtained. Participant then ingested a capsule containing
placebo, 35 mg hydrocortisone, or 80 mg propranolol.
During the next 75 min, participants completed several
computer-based questionnaires and were instructed to
remain in the laboratory and read (reading material was
provided). At t=75 min after ingestion, participants heart
rate and blood pressure were again assessed and saliva
measurements obtained. At approximately t=90, the script-
driven imagery task took place. After a baseline period of
60 s, a neutral script, which was similar for all participants,
was played with the VSRRP software program while
Fig. 1 Schematic overview of
the test sessions
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physiological reactions were measured. Then, for 60 s,
participants were instructed to imagine the story they had
heard. After another baseline period of 60 s, their personal
script was played, followed by a 60-s period in which they
had to imagine reliving the event. After the imagery task,
participant filled in the emotionality questionnaire again.
The neutral story was always followed by the personal
script to prevent emotions elicited by the personal scripts
from persisting into the neutral story. In the third session,
the same procedures regarding the imagery tasks were
repeated, also followed by the emotionality questionnaire.
In an 8-month follow-up telephone interview, participants
were asked once more to rate the intensity of the emotions
related to their personal memory.
Data analysis
The effects of the treatment (placebo versus cortisol or
propranolol) on physiological and subjective measures were
analyzed using RM-ANOVAs with time as within-subject
and group as between-subject factors. Log-transformed
values were used for cortisol and alpha-amylase values to
account for non-normality. The change in subjective
emotionality of the story over time was analyzed using an
repeated-measures multivariate analysis of variance (RM-
MANOVA) with group as a between-subject factor and
time (session 1, session 2, session 3, and 8 months follow-
up) as a within-subject factor. For the analyses of the
physiological responding to the script-driven imagery, mean
SCL and heart rate were calculated for 60-s periods by
averaging measurements of three consecutive 20-s periods.
Reactions to the neutral and personal script were calculated
by subtracting the 1-min listening and 1-min imagery
periods from the 1-min baseline period before the respec-
tive story. This resulted in two neutral change scores and
two emotional script change scores on both sessions 2 and
3 for each group. These change scores were square root-
transformed prior to analyses. We applied RM-ANOVAs
with group as a between-subject factor and session (session
2 versus session 3), emotion (neutral versus personal
script), and part (listening versus imagining) as within-
subject factors. In a multivariate RM analysis, we included
heart rate and SCL change scores as dependent variables.
Then, separate RM-ANOVAs were calculated for each
dependent change score separately. Greenhouse–Geisser
corrected p values were used when indicated by violated
sphericity. Analyses were performed with SPSS 14.0
(SPSS, Chicago, IL, USA). The criterion for statistical
significance was p<0.05.
Results
Treatment effects
Cortisol administration induced the expected increase in free
saliva cortisol levels, as indicated by a significant time by
group interaction between the cortisol and placebo groups [F
(2, 112)=345.96, p<0.001; see Table 2]. Cortisol did not
affect alpha-amylase levels, heart rate, and systolic (SBP) or
diastolic (DBP) blood pressure [F(2, 93)=2.34, p=0.10; F(2,
87)=1.86, p=0.71; F(2, 113)=0.56, p=0.59; F(2, 114)=
1.71, p=0.18, respectively], see also Fig. 2a–d.
Propranolol lowered adrenergic activation as expected,
indicated by significant time by group interactions between
the propranolol and placebo groups for alpha-amylase, heart
rate, and SBP [F(2, 111)=3.88, p<0.02; F(2, 101)=16.25,
p<0.001; F(2, 101)=10.76, p<0.001, respectively]. All
measures declined stronger over time in the propranolol
group compared to the placebo group (see Fig. 2a–d). The
general decline in adrenergic activation in all groups from
t=0 to t=75 might be due to the 75-min restful waiting
period. Although DBP also showed a time by group
interaction [F(2, 125)=4.15, p<0.02], post hoc t test revealed
no significantly lower DBP at any of the time points (all
ps>0.09). Propranolol also slightly increased free saliva
cortisol over time compared to the control group [F(2, 94)=
12.74, p<0.001] (see Tollenaar et al. 2008c).
No effects of treatment over time were found on
subjective feelings of tension, anxiety, insecurity, irritation,
motivation, mood, and tiredness (all ps>0.39). We did find
an interaction effect of group with time on anxiety,
although not significant [F(5, 186)=2.21, p=0.06], sug-
gesting that the propranolol group reported lower anxious
Table 2 Free salivary cortisol in nanomoles per liter (±SEM) in each treatment group
Time
Group t=0 t=75 t=110 t=135
Placebo 9.11 (0.96) 5.00 (0.45) 4.34 (0.39) 4.58 (0.44)
Cortisol 7.47 (0.71) 206.61 (17.53)* 134.79 (9.01)* 99.37 (5.55)*
Propranolol 8.01 (0.47) 6.38 (0.78) 8.29 (1.05)** 9.67 (1.27)**
*p<0.001, significant increase in cortisol levels in the cortisol group versus the placebo group; **p<0.001, significant increase in cortisol levels
in the propranolol group versus the placebo group
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feelings over time compared to the control group. However,
post hoc t tests revealed no significantly lower anxious
feelings at any of the time points in the propranolol group
versus the control group (all ps>0.11). Furthermore, all
treatments were well-tolerated and participants were not
aware which treatment they received (Pearson χ2(6)=5.71,
p=0.46).
Baseline values
In the first session, a baseline period was measured for heart
rate and SCL. No differences were found between the groups
(MANOVA: F(6, 148)=0.67, p=0.61; separate ps>0.34; see
Table 3). The groups also did not differ on any of the
emotionality ratings that were given to their personal script
on the first session (MANOVA: F(16, 140)=0.47, p=0.96;
all separate ps>0.16; see Table 3).
Emotional ratings over time
To study the change over time in the subjective emotionality
ratings related to the personal script, we performed a RM-
MANOVA with time (session 1, session 2, session 3, and
follow-up) as a within-subject factor and group as a between-
subject factor. Follow-up was completed by 74 participants.
The overall MANOVA revealed no significant group by time
Table 3 Mean (±SD) physiological and subjective baseline values on session 1 for the three treatment groups
Groupa
Baseline value (session 1) Placebo Cortisol Propranolol
Heart rate (bpm) 65.85 (8.27) 64.33 (8.61) 65.17 (9.54)
SCL (μS) 16.91 (5.54) 18.42 (6.16) 16.18 (6.13)
Arousal 4.04 (1.54) 4.54 (1.61) 4.33 (1.82)
Negative valence 4.81 (1.47) 4.96 (1.56) 5.15 (1.32)
Re-experiencing 4.19 (1.47) 4.31 (1.35) 4.26 (1.38)
Fear 2.54 (1.27) 2.81 (1.58) 2.85 (1.46)
Anger 2.77 (1.68) 3.42 (1.65) 3.37 (1.84)
Sadness 3.77 (1.77) 4.08 (1.85) 4.41 (1.62)
Importance 3.65 (1.92) 4.27 (1.89) 4.63 (1.74)
Thought about 4.19 (1.55) 4.54 (1.68) 4.56 (1.34)
On the subjective emotionality ratings, minimum scores were 1 (very low) and maximum scores were 7 (very high)
SCL skin conductance level, bpm beats per minute, μS microsiemens
a No effects of group on any of the baseline measures were found (all ps>0.16)
Fig. 2 Physiological measures
(mean±SEM) of adrenergic ac-
tivation on session 2 before
treatment (t=0) and after treat-
ment (t=75, 110, and 135 min):
a alpha-amylase, b heart rate, c
SBP, d DBP. U/L units per liter,
bpm beats per minute, mmHg
millimeter of mercury. *p<0.01,
significant difference in the pro-
pranolol versus the placebo
group; #p<0.05, significant dif-
ference in the propranolol versus
the placebo group
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interactions [F(42, 1,272)=0.72, p=0.91], but significant
declines over time [F(21, 627)=5.43, p<0.001] reflected in
significant univariate ANOVA tests for all measures (all
ps<0.001, except for fear p<0.02). The decline in subjective
emotional appraisals was already significant at session 3
[F(14, 302)=3.90, p<0.001].
Physiological responses to the scripts
Figure 3 shows the raw heart rate and SCL responses to
both the neutral and personal emotional script in the three
groups. For every session, responses were divided into the
listening and imagery responses. The RM-MANOVA on
heart rate and SCL showed a main effect of emotion [F(2,
66)=24.38, p<0.001], a main effect of day [F(2, 66)=4.84,
p<0.02], a main effect of part [F(2, 66)=36.36, p<0.001],
and a day by emotion interaction [F(2, 66)=5.08, p<0.01),
as well as a part by day [F(2, 66)=3.52, p<0.05] and a part
by emotion interaction [F(2, 66)=5.64, p<0.01]. No main
or interaction effects of group were found (all ps>0.10),
thus not revealing the expected emotion by group or day by
emotion by group interactions.
The separate RM-ANOVA for SCL responses revealed the
same main and interaction effects as in the RM-MANOVA
[days: F(1, 76)=8.99, p<0.01; emotion: F(1, 76)=53.01,
p<0.001; part: F(1, 76)=92.95, p<0.001; day by emotion:
F(1, 76)=7.56, p<0.01); part by day (F(1, 76)=9.43,
p<0.01); and part by emotion interaction: F(1, 76)=18.46,
p<0.001]. Overall, the emotional script seemed to elicit
higher SCL responses than the neutral story, and on the third
session, responses were smaller than on the second session.
To examine the day by emotion interaction, we split the
analyses by emotion. It was revealed that there was no day
effect for the neutral story [F(1, 76)=0.033, p=0.86], but a
significant day effect for the emotional script [F(1, 76)=
13.98, p<0.001] with lower SCLs to the emotional script on
the third session compared to the second session (see also
Fig. 3c,d). Furthermore, overall responses to the listening
part were higher than to the imagery part. To examine the
part by day and the part by emotion interactions, we split the
analyses by part. During both the listening and imagining
part, the main emotion effect was present, although slightly
stronger during listening than imagery [F(1, 76)=75.04, p<
0.001 and F(1, 76)=31.90, p<0.001, respectively]. The day
by emotion interaction was also present for both parts, but
the main effect for day was only present for the imagery part
[F(1, 76)=23.30, p<0.001; listening part: F(1, 76)=1.22, p=
0.27], reflecting a greater decrease in physiological response
over time for imagery.
For heart rate responses, we found no effects of day,
emotion, or part (all ps>0.24) as in the RM-MANOVA, but
we did find a significant part by emotion by group
interaction [F(2, 67)=3.16, p<0.05] and a trend for a part
by day by group interaction [F(2, 67)=2.54, p=0.09]. When
breaking up the analyses in the listening and imagery part,
we found a marginally significant emotion effect only during
imagery [F(1, 75)=3.64, p=0.06] with higher heart rate
change scores for the neutral compared to the emotional
story (see Fig. 3a,b). Furthermore, during imagery, we found
a trend for a day by group interaction [F(2, 75)=2.84,
p=0.07], revealing that the propranolol group showed higher
heart rate responses on session 3 compared to session 2 [F(1,
26)=6.98, p<0.02], while this affect was not present in the
control and cortisol groups (ps>0.80).
Fig. 3 Heart rate (a, b) and
SCL (c, d) responses to both
the neutral story and personal
emotional script in the three
groups on both session 2 (after
treatment, left) and session 3
(1 week later, right). Responses
were divided into listening and
imagery responses. bpm beats
per minute, μS microsiemens
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Because differences between groups in age and BDI
scores were (borderline) significant, we entered them as
covariates in the above analyses. Still none of the expected
group effects revealed significance (all ps>0.29), and the day
by group interaction during the imagery part remained
borderline significant for heart rate [F(2, 72)=3.01, p=0.06].
Discussion
The present study examined the immediate and prolonged
effects of both cortisol and propranolol administration on
physiological responses to script-driven imagery of nega-
tive, disturbing memories in healthy young men after
reactivation of these memories. No diminishing effect of
either propranolol or cortisol on psychophysiological
responding to the script-driven imagery of emotional
memories was found. The subjective emotional experience
of the memories was not affected by cortisol or propranolol
either. Even though propranolol was found to attenuate
physiological responding (heart rate and SCL) to traumatic
scripts in PTSD patients (Brunet et al. 2008), we did not
find such effects to negative emotional scripts in healthy
young men. These results also contrast the finding by Het
and Wolf (2007) that cortisol can affect the emotional
experience of negative events and the finding that cortisol
can reduce the intensity of traumatic memories (Aerni et al.
2004). However, methodological differences between these
studies and our study might have caused these conflicting
findings, as we will discuss below.
While our hypotheses regarding cortisol and propranolol
were not confirmed, we were able to evoke physiological
responses to personal emotional scripts in a healthy male
population. That is, the emotional scripts led to significant-
ly higher SCL responses than a neutral story, although not
to any significant increases in heart rate. Heart rate even
seemed to be lower during imagery of the emotional script
than during the neutral script. This is in line with previous
research showing heart rate decelerations during attention
to emotional (auditory) stimuli in healthy humans (Bradley
and Lang 2000; Palomba et al. 1997; van Stegeren et al.
2002). Within the propranolol group, heart rate responses to
the neutral and emotional script were higher 1 week after
treatment than during treatment. This is probably due to the
fact that propranolol administration on the second session
lowered heart rate and adrenergic functioning overall, and
might thus have led to lower heart rate responses in the
second session. Therefore, these sessions cannot be
compared validly. Overall, the SCL responses were higher
when participants listened to their script than when
imagining the script, and responses to imaging decreased
more over time. This might be important for future studies
using script-driven imagery tasks to take into account, since
the two processes could be differently affected by drug
treatment.
Furthermore, the subjective emotional and arousal
responses to the memories decreased steadily over time,
from session 1 to session 3 and 8 months later, and likewise
the SCL responses to the emotional scripts decreased from
the second to the third session. However, while physiolog-
ical reactions to the emotional memories might have
diminished over time, participants might also have been
less surprised the second time they heard their story (on the
third session). That is, even though subjects knew their
memory would be part of the study, on the second session,
they were not aware they would hear an audio version of it.
There might be several reasons why cortisol and
propranolol did not attenuate physiological responses to
script-driven imagery of negative, disturbing memories in
healthy young men after reactivation of these memories.
First of all, heart rate was not heightened in response to the
emotional script in the placebo group on either of the two
sessions, and SCLs were not heightened in response to
emotional imagery in the placebo group on the last session.
Therefore, cortisol and propranolol could only act on SCL
responses during the second (treatment) session and on
SCL responses to the listening part during the third session,
on which we expected the reconsolidation effects. The
negative disturbing events that the young, healthy males in
our studies had described were probably much less intense
than traumatic memories in PTSD populations and hence
attenuation of physiological responding might not have
been possible due to floor effects. However, we did elicit
consistent SCL responses during listening to the emotional
scripts and these negative memories were described as
overall important and were thought about more often than
other memories. This might lead to consideration of a
second possibility, namely, that the dose was too low to
affect the physiological responding. In the studies by
Brunet et al. (2008) and Pitman et al. (2002), multiple
doses or longer-acting propranolol were used. These studies
involved patient groups that are characterized by high blood
pressure and heart rate levels overall, and therefore, larger
doses of propranolol might be needed to reduce physiolog-
ical responding. However, reconsolidation of emotional
memories could possibly take longer than a few hours, and
longer-acting doses might, therefore, be needed to affect
these reconsolidation processes. Cortisol on the other hand,
was given in lower doses in the clinical studies by Aerni et
al. (2004) and Schelling et al. (2004), but the doses were
given daily instead of once, leading to active cortisol during
potentially multiple memory reactivations. While in the
present study the dose may have been too low or short-
acting to obtain reductions in physiological arousal in
response to personalized scripts, in the same population as
the present study, we did find long-term impairing effects of
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the 35-mg cortisol dose on declarative memory retrieval
(Tollenaar et al. 2008c). Taken together, this might lead to
the possibility that cortisol only affects declarative memory
retrieval and not the physiologically arousing components
of the memory. Perhaps longer-acting doses or more
frequent administration of cortisol and propranolol might
lead to attenuating physiological responding in a healthy
population as well.
Our study differed in several aspects to the study in
PTSD patients by Brunet et al. (2008). As mentioned,
different and longer-acting doses of propranolol were used
than in our study. Furthermore, in the study by Brunet et al.,
propranolol was given after the script preparation procedure
that was used to reactivate the event. In our study, the script
was prepared a week before drug administration and only
the listening to and imagining of the memory, which lasted
2 min, was used to reactivate the memory under the
influence of the drugs. This might have been a suboptimal
reactivation procedure to affect reconsolidation. In addition,
reactivation of the memory a week before treatment might
have promoted extinction of or habituation to the memory.
Hence, it cannot be ruled out that the reactivation procedure
was not optimal to find immediate or prolonged effects of
cortisol or propranolol on physiological responding.
Another issue that merits consideration is the timing of
the drugs. In the present study, we administered cortisol and
propranolol before reactivation. This way both retrieval and
postretrieval processes are within the active time window of
the drugs. In animal research, these substances are usually
given after reactivation to only affect postretrieval process-
es. In the study by Brunet et al. (2008), a similar
postreactivation approach was taken, although in the
clinical trials mentioned in the introduction (Aerni et al.
2004; Pitman et al. 2002; Soravia et al. 2006; Vaiva et al.
2003), cortisol and propranolol were administered during a
longer time span or before retrieval as well. The fact that, in
this study, drugs were active during both retrieval and
postretrieval processes could potentially explain our non-
results with regard to the prolonged effects of cortisol and
propranolol. That is, if memory retrieval is reduced by
cortisol or propranolol, the emotional memories might not
be sufficiently reactivated and hence reconsolidation pro-
cesses could possibly not be blocked. However, psycho-
physiological responding under the influence of cortisol did
not seem to be affected, indicating that the emotional
memories were adequately reactivated at the time of the
treatment. Propranolol, on the other hand, did lower heart
rate responses during treatment, which may have reduced
the possibility to affect reconsolidation processes.
A last factor to take into account is that we studied only
males. Females might be more reactive to imagery of
emotional memories or more sensitive to the effects of
cortisol and propranolol, although in the clinical studies no
gender effects are reported. Het and Wolf (2007) did find
attenuating effects of cortisol on the experience of a
negative emotional event in healthy women while we did
not find such effects on negative emotional memories in
men, suggesting that gender may indeed play an important
role. Our negative findings on cortisol and propranolol
could also be due to power problems. However, our group
sizes compare well to the clinical studies, and as reported
above, before we did find an impairing effect of cortisol on
declarative memory retrieval in the same population.
We were not able to find an attenuating effect of cortisol
on physiological responding to memories in healthy men,
but whether cortisol can attenuate physiological responding
in PTSD remains unknown. Potentially, the attenuating
effects of cortisol are only present in individuals that are
hyperaroused. Future studies using cortisol or propranolol
in healthy populations could use different or longer-acting
doses, more frequent administration, or different timing
protocols with regard to reactivation of the memories.
Future studies could also investigate more elaborate
reactivation paradigms or consider vulnerable populations
to elicit higher emotional responses to the memories. In
addition, both males and females should be included in
future investigations. Conditioning paradigms would also
be a good way to measure and replicate animal studies on
postretrieval processes. At this point, there are only
preliminary data available, showing reducing effects of
propranolol on a conditioned fear response in healthy
subjects when administered during reactivation of the fear
memory (Miller et al. 2004).
To conclude, the present study was able to measure
physiological responding to script-driven imagery of
emotional memories on two consecutive occasions in
healthy young men, reflected in heightened SCL responses
and lowered heart rate responses. Furthermore, we mea-
sured the subjective emotional responses to these memories
over a long time span of 8 months. Reductions in emotional
appraisal of the memories were shown within 3 weeks and
even further up to 8 months. We did not find any immediate
or prolonged effects of either cortisol or propranolol on
these physiological and subjective measures. We might
conclude that the effect of propranolol on physiological
responses to emotional memories is specific to clinical
groups characterized by hyper-responsiveness, like PTSD,
although differences in study designs might partly explain
these divergent findings. Furthermore, the effects of cortisol
on physiological responses to emotional memories in
clinical groups should still be explored, in addition to its
effect on declarative memory retrieval. More knowledge on
the mechanisms behind propranolol and cortisol in treating
disorders like PTSD and phobias might lead to more
efficient and safe use of these drugs (for discussions, see
Glannon 2006; van Stegeren 2005).
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